These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 25644017)

  • 1. Expression and characterization of bifunctional fusion proteins possessing antitumor and thrombolytic function for targeting therapy.
    Hui J; Lin JS; Hu Y; Li H; Hu FQ
    Biotechnol Appl Biochem; 2016; 63(2):170-7. PubMed ID: 25644017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of novel chimeric proteins through the truncation of SEC2 and Sak from Staphylococcus aureus.
    Hui J; Yu XJ; Cui XJ; Mu T; Lin JS; Ni P; Li H; You S; Hu FQ
    Biosci Biotechnol Biochem; 2014; 78(9):1514-21. PubMed ID: 25209498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of novel bifunctional chimeric proteins possessing antitumor and thrombolytic activities.
    Hui J; Dai Y; Bian Y; Li H; Cui X; Yu X; You S; Hu F
    J Microbiol Biotechnol; 2012 Jul; 22(7):894-901. PubMed ID: 22580307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The construction of a bifunctional fusion protein consisting of SEC2 and EGFP.
    Liu Y; Xu M; Li X; Sun J; Zhang C; Zhang H
    Biotechnol Appl Biochem; 2014; 61(5):565-71. PubMed ID: 24397332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells.
    Schanzer JM; Fichtner I; Baeuerle PA; Kufer P
    J Immunother; 2006; 29(5):477-88. PubMed ID: 16971804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression, purification, refolding, and characterization of octreotide-interleukin-2: a chimeric tumor-targeting protein.
    Jiang J; Deng L; He L; Liu H; Wang C
    Int J Mol Med; 2011 Oct; 28(4):549-56. PubMed ID: 21687929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation and In Vitro Evaluation of Antitumor Activity of TGFαL3-SEB as a Ligand-Targeted Superantigen.
    Yousefi F; Mousavi SF; Siadat SD; Aslani MM; Amani J; Rad HS; Fooladi AA
    Technol Cancer Res Treat; 2016 Apr; 15(2):215-26. PubMed ID: 25759426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of ovarian cancer growth by a tumor-targeting peptide that binds eukaryotic translation initiation factor 4E.
    Ko SY; Guo H; Barengo N; Naora H
    Clin Cancer Res; 2009 Jul; 15(13):4336-47. PubMed ID: 19458052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
    Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
    Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Delivery of Interferon Gamma Using a Recombinant Fusion Protein of a Fibrin Clot-Binding Peptide With Interferon Gamma for Cancer Gene Therapy.
    Ando M; Fujimoto M; Takahashi Y; Nishikawa M; Hamana A; Takakura Y
    J Pharm Sci; 2017 Mar; 106(3):892-897. PubMed ID: 27939375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
    Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
    Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted antitumor prodrug therapy using CNGRC-yCD fusion protein in combination with 5-fluorocytosine.
    Li JJ; Chang SF; Liau II; Chan PC; Liu RS; Yen SH; Wang HE; Chang CA
    J Biomed Sci; 2016 Jan; 23():15. PubMed ID: 26801910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Characterization of the Recombinant Human VEGF-EGF Dual-Targeting Fusion Protein as a Drug Delivery System.
    Li JJ; Lan KL; Chang SF; Chen YF; Tsai WC; Chiang PH; Lin MH; Fischer WB; Shih YS; Yen SH; Liu RS; Tsay YG; Wang HE; Chang CA
    Bioconjug Chem; 2015 Dec; 26(12):2481-96. PubMed ID: 26525951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The in vitro antitumor effect and in vivo tumor-specificity distribution of human-mouse chimeric antibody against transferrin receptor.
    Qing Y; Shuo W; Zhihua W; Huifen Z; Ping L; Lijiang L; Xiaorong Z; Liming C; Daiwen X; Yu H; Wei X; Min F; Zuohua F; Guanxin S
    Cancer Immunol Immunother; 2006 Sep; 55(9):1111-21. PubMed ID: 16341531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation.
    Frey K; Zivanovic A; Schwager K; Neri D
    Integr Biol (Camb); 2011 Apr; 3(4):468-78. PubMed ID: 21225052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells.
    Scherf U; Benhar I; Webber KO; Pastan I; Brinkmann U
    Clin Cancer Res; 1996 Sep; 2(9):1523-31. PubMed ID: 9816329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression and bioactivity analysis of staphylococcal enterotoxin C2].
    Xue Q; Ying YB; Pan YQ; Li DX; Sun HY; Chen SQ
    Yao Xue Xue Bao; 2006 May; 41(5):406-11. PubMed ID: 16848315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pronounced antitumor efficacy by extracellular activation of a doxorubicin-glucuronide prodrug after adenoviral vector-mediated expression of a human antibody-enzyme fusion protein.
    de Graaf M; Pinedo HM; Oosterhoff D; van der Meulen-Muileman IH; Gerritsen WR; Haisma HJ; Boven E
    Hum Gene Ther; 2004 Mar; 15(3):229-38. PubMed ID: 15018732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photochemical internalization augments tumor vascular cytotoxicity and specificity of VEGF(121)/rGel fusion toxin.
    Weyergang A; Cheung LH; Rosenblum MG; Mohamedali KA; Peng Q; Waltenberger J; Berg K
    J Control Release; 2014 Apr; 180():1-9. PubMed ID: 24531010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and activity analysis of a new fusion protein targeting ovarian cancer cells.
    Su M; Chang W; Wang D; Cui M; Lin Y; Wu S; Xu T
    Oncol Rep; 2015 Sep; 34(3):1337-44. PubMed ID: 26166362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.